Altuvoct is a medicine used to prevent and treat bleeding in adults and children with haemophilia A. Haemophilia A is an inherited bleeding disorder caused by a lack of factor VIII, a protein that helps the blood clot. Haemophilia A is rare, and Altuvoct was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 28 June 2019. Altuvoct contains the active substance efanesoctocog alfa.
Therapeutic Indication
### Therapeutic indication Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency). Altuvoct can be used for all age groups.
Therapeutic Area (MeSH)
ATC Code
B02BD02
ATC Item
coagulation factor VIII
Pharmacotherapeutic Group
Antihemorrhagics
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| Efanesoctocog alfa | N/A | Efanesoctocog alfa |
EMA Name
Altuvoct
Medicine Name
Altuvoct
Aliases
N/A
